Tags

Type your tag names separated by a space and hit enter

Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease.
Gastroenterol Clin North Am 2012; 41(4):821-42GC

Abstract

Definitive curative strategies for inflammatory bowel disease remain challenging for physicians and patients. For decades, probiotic organisms have been used in various gastrointestinal diseases. Only recently has comprehension of the pathophysiology of inflammatory bowel disease developed to the point where the significance of the host gastrointestinal microbial population is seen to have marked influence on the initiation and ongoing inflammatory processes of Crohn disease and ulcerative colitis. Well-designed, large randomized controlled trials using probiotics in patients with inflammatory bowel disease are required for probiotics to become mainstream therapy.

Authors+Show Affiliations

Division of Gastroenterology, University of Alberta, 2-14A Zeidler Building, 130 University Campus, Edmonton, Alberta T6G 2X8, Canada. Richard.fedorak@ualberta.caNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23101689

Citation

Fedorak, Richard, and Denny Demeria. "Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease." Gastroenterology Clinics of North America, vol. 41, no. 4, 2012, pp. 821-42.
Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41(4):821-42.
Fedorak, R., & Demeria, D. (2012). Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterology Clinics of North America, 41(4), pp. 821-42. doi:10.1016/j.gtc.2012.08.003.
Fedorak R, Demeria D. Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2012;41(4):821-42. PubMed PMID: 23101689.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. AU - Fedorak,Richard, AU - Demeria,Denny, Y1 - 2012/09/28/ PY - 2012/10/30/entrez PY - 2012/10/30/pubmed PY - 2013/4/30/medline SP - 821 EP - 42 JF - Gastroenterology clinics of North America JO - Gastroenterol. Clin. North Am. VL - 41 IS - 4 N2 - Definitive curative strategies for inflammatory bowel disease remain challenging for physicians and patients. For decades, probiotic organisms have been used in various gastrointestinal diseases. Only recently has comprehension of the pathophysiology of inflammatory bowel disease developed to the point where the significance of the host gastrointestinal microbial population is seen to have marked influence on the initiation and ongoing inflammatory processes of Crohn disease and ulcerative colitis. Well-designed, large randomized controlled trials using probiotics in patients with inflammatory bowel disease are required for probiotics to become mainstream therapy. SN - 1558-1942 UR - https://www.unboundmedicine.com/medline/citation/23101689/Probiotic_bacteria_in_the_prevention_and_the_treatment_of_inflammatory_bowel_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0889-8553(12)00097-0 DB - PRIME DP - Unbound Medicine ER -